ZA201906127B - Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use - Google Patents

Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Info

Publication number
ZA201906127B
ZA201906127B ZA2019/06127A ZA201906127A ZA201906127B ZA 201906127 B ZA201906127 B ZA 201906127B ZA 2019/06127 A ZA2019/06127 A ZA 2019/06127A ZA 201906127 A ZA201906127 A ZA 201906127A ZA 201906127 B ZA201906127 B ZA 201906127B
Authority
ZA
South Africa
Prior art keywords
dimethoxyquinolin
dicarboxamide
cyclopropane
fluorophenyl
oxy
Prior art date
Application number
ZA2019/06127A
Other languages
English (en)
Inventor
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201906127(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ZA201906127B publication Critical patent/ZA201906127B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
ZA2019/06127A 2017-05-26 2019-09-17 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use ZA201906127B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
ZA201906127B true ZA201906127B (en) 2022-11-30

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/06127A ZA201906127B (en) 2017-05-26 2019-09-17 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Country Status (20)

Country Link
US (3) US11279675B2 (enExample)
EP (1) EP3630726B1 (enExample)
JP (3) JP7166292B2 (enExample)
KR (1) KR102611445B1 (enExample)
CN (1) CN110621662B (enExample)
AU (1) AU2018272088C1 (enExample)
CA (1) CA3060370A1 (enExample)
DK (1) DK3630726T3 (enExample)
EA (1) EA039654B1 (enExample)
ES (1) ES2909390T3 (enExample)
HU (1) HUE058196T2 (enExample)
IL (1) IL270780B2 (enExample)
MA (1) MA48776A (enExample)
MX (1) MX2019012505A (enExample)
PL (1) PL3630726T3 (enExample)
PT (1) PT3630726T (enExample)
SG (1) SG11201909161PA (enExample)
UA (1) UA127760C2 (enExample)
WO (1) WO2018218233A1 (enExample)
ZA (1) ZA201906127B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384828B (es) * 2014-02-14 2025-03-14 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
PL3630726T3 (pl) * 2017-05-26 2022-05-09 Exelixis, Inc. Krystaliczne stałe sole N-{4-[(6,7-dimetoksychinolin-4-ylo)oksy]fenylo}-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksyamidu, sposoby ich wytwarzanie oraz ich zastosowania
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CR20210375A (es) 2018-12-13 2021-08-18 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
CA3139148A1 (en) * 2019-06-03 2020-12-10 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
CN118974017A (zh) 2022-03-01 2024-11-15 斯索恩有限公司 卡博替尼的l-(+)-酒石酸盐及其固体形式
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
DK2387563T4 (da) * 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
FI2621481T4 (fi) 2010-09-27 2023-01-13 Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
EA033513B1 (ru) * 2011-02-10 2019-10-31 Exelixis Inc Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
BR212013028314U2 (pt) 2011-05-02 2015-11-03 Exelixis Inc método para tratar câncer e dor de câncer de osso
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
IN2014CN04067A (enExample) 2011-11-08 2015-10-23 Exelixis Inc
WO2013070903A1 (en) 2011-11-08 2013-05-16 Exelixis, Inc. Method of quantifying cancer treatment
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
MX384828B (es) * 2014-02-14 2025-03-14 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
WO2015177758A1 (en) * 2014-05-23 2015-11-26 Mylan Laboratories Ltd Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274332B1 (en) 2015-03-25 2018-12-19 Sandoz AG Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
CN109922790B (zh) * 2016-09-12 2022-06-14 珠海贝海生物技术有限公司 卡博替尼制剂
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
PL3630726T3 (pl) * 2017-05-26 2022-05-09 Exelixis, Inc. Krystaliczne stałe sole N-{4-[(6,7-dimetoksychinolin-4-ylo)oksy]fenylo}-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksyamidu, sposoby ich wytwarzanie oraz ich zastosowania

Also Published As

Publication number Publication date
WO2018218233A1 (en) 2018-11-29
EA201992803A1 (ru) 2020-04-16
KR20200010205A (ko) 2020-01-30
CA3060370A1 (en) 2018-11-29
IL270780A (en) 2020-01-30
DK3630726T3 (da) 2022-03-07
JP2024036690A (ja) 2024-03-15
EP3630726A1 (en) 2020-04-08
JP7437460B2 (ja) 2024-02-22
PT3630726T (pt) 2022-03-02
EP3630726B1 (en) 2021-12-22
US20210261509A1 (en) 2021-08-26
IL270780B2 (en) 2025-04-01
AU2018272088B2 (en) 2022-06-16
MA48776A (fr) 2020-04-08
JP7166292B2 (ja) 2022-11-07
JP7659097B2 (ja) 2025-04-08
AU2018272088A8 (en) 2019-10-24
ES2909390T3 (es) 2022-05-06
CN110621662A (zh) 2019-12-27
NZ757564A (en) 2025-05-02
KR102611445B1 (ko) 2023-12-06
AU2018272088A1 (en) 2019-10-17
US12227481B2 (en) 2025-02-18
US11731941B2 (en) 2023-08-22
UA127760C2 (uk) 2023-12-27
US20240010621A1 (en) 2024-01-11
EA039654B1 (ru) 2022-02-22
AU2018272088C1 (en) 2022-09-22
IL270780B1 (en) 2024-12-01
HUE058196T2 (hu) 2022-07-28
JP2020521732A (ja) 2020-07-27
SG11201909161PA (en) 2019-10-30
PL3630726T3 (pl) 2022-05-09
US11279675B2 (en) 2022-03-22
MX2019012505A (es) 2019-12-19
CN110621662B (zh) 2023-06-23
JP2022145852A (ja) 2022-10-04
US20220162166A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
ZA201906127B (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
ZA201605424B (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
IL324126A (en) Structural formula of (s)-(4,5-dihydro-7h-thieno[2,3-c]pyren-7-yl)-n-methylmethamine HCl salt and dispersants
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
IL283480A (en) Solid forms of lometaferon and lometaferon salts and processes for preparing lometaferon
EP3551612A4 (en) PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
PH12020500446A1 (en) Bisamide sarcomere activating compounds and uses thereof
MA49696A (fr) Sel d'un composé dérivé d'aminopyridine, forme cristalline de celui-ci, et son procédé de préparation
EP3453703A4 (en) CRYSTALLINE FORM OF TAFAMIDIS-METHYLGLUCAMINE SALT AND MANUFACTURING METHOD AND APPLICATION THEREOF
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
IL263004B (en) A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
ZA202200964B (en) Salts of a compound, crystal forms of the salts and preparation method and use thereof
WO2019240698A3 (en) Oral pharmaceutical composition comprising posaconazole
EP4013422A4 (en) CRYSTALLINE FORMS OF QUINOLINE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND THEIR METHODS OF USE
SG11202111558VA (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
EP3901157A4 (en) NEW COMPOUND AND HAIR GROWTH STIMULATOR COMPOSITION INCLUDED THIS
HK40105168A (zh) 药学化合物、其盐类、其制剂和其制备和使用方法
EP3889157C0 (en) SALT AND CRYSTALLINE FORM OF A FUROPYRIMIDINE COMPOUND AND THEIR PHARMACEUTICAL USE
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof
PL3898612T3 (pl) Podstawione pirydynyloksybenzeny, ich sole oraz zastosowanie jako aktywne składniki herbicydowe
HK40075950A (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
HK40004900A (en) Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
HK1232527A1 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]- phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use